Skip to Content

M14-212 A Phase 2 Study of ABT-199 in Subjects with Acute Myelogenous Leukemia (AML)

Objective
This is a clinical trial of ABT-199 that will be administered by mouth, which is investigational.
IRB Protocol Number
13-2463
Principal Investigator(s)
DAN POLLYEA

Cancer Trials

  • Leukemia/Myelodysplasia
Sponsor(s)
AbbVie
Contact
DEREK SCHATZ at 720-848-0628
or DEREK.SCHATZ@UCDENVER.EDU
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility. A treatment period that can last until your disease worsens or you no longer tolerate study drug treatment. A follow up period will consist of a clinic visit and phone calls. // Eligibility criteria include but are not limited to 18 years or older in patients with AML that is relapsed or refractory, or patients with untreated AML who cannot tolerate standard therapy.